CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 17 enrolled
Drug / intervention
Fluciclovine F18 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03707184
NCT03707184Phase 2Completed
CompareCT.gov

[18F]Fluciclovine Companion Imaging Study to Radium-223 and Radiotherapy in Hormone-Naive Men With Oligometastatic Prostate Cancer to Bone (RROPE) Study

University of Utah·interventional·Posted Oct 16, 2018·Updated Nov 29, 2024

In Brief

A Phase 2 clinical trial evaluating Computed Tomography, Fluciclovine F18, and 1 other intervention for Metastatic Prostate Carcinoma and 2 related conditions. Completed, enrolled 17 participants across 1 site.

Detailed Summary

This trial studies how well fluciclovine 18F PET/CT imaging works in assessing hormone-naive men with prostate cancer that has spread to the bone. Fluciclovine 18F is a radioactive drug used to measure tumor growth. PET/CT uses x-rays to take pictures inside the body. Comparing results of fluciclovine 18F PET/CT imaging may help doctors predict a patient's response to treatment and help plan the best treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedOct 16, 2018
Enrollment StartOct 2, 2018
Primary CompletionFeb 3, 2022
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 7.7 years ago

Interventions

Computed Tomographyprocedure

Undergo PET/CT scan

Fluciclovine F18drug

Given IV

Positron Emission Tomographyprocedure

Undergo PET/CT scan